Trials / Recruiting
RecruitingNCT05609578
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Mirati Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Adagrasib oral dose of 400 mg twice daily tablets | oral dose of 400 mg twice daily tablets |
| COMBINATION_PRODUCT | Pembrolizumab | IV infusion once every 3 weeks |
| COMBINATION_PRODUCT | Chemotherapy: Pemetrexed | IV infusion once every 3 weeks |
| COMBINATION_PRODUCT | Cisplatin/Carboplatin | IV infusion once every 3 weeks |
Timeline
- Start date
- 2022-11-22
- Primary completion
- 2026-06-01
- Completion
- 2026-12-01
- First posted
- 2022-11-08
- Last updated
- 2025-08-17
Locations
166 sites across 14 countries: United States, Brazil, Chile, France, Georgia, Greece, Hungary, Italy, Malaysia, Poland, Serbia, Spain, Switzerland, Thailand
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05609578. Inclusion in this directory is not an endorsement.